CoChat
Cited by 190

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation: The MMVAR/IFM 2005-04 Randomized Phase III Trial From the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

Open access
Garderet, Laurent, Iacobelli, Simona, Moreau, Philippe, Dib, Mamoun, Lafon, Ingrid, Niederwieser, Dietger, Masszi, Tamas, Fontan, Jean, Michallet, Mauricette, Gratwohl, Alois, Milone, Giuseppe, Doyen, Chantal, Pegourie, Brigitte, Hajek, Roman, Casassus, Philippe, Kolb, Brigitte, Chaleteix, Carine, Hertenstein, Bernd, Onida, Francesco, Ludwig, Heinz, Ketterer, Nicolas, Koenecke, Christian, van Os, Marleen, Mohty, Mohamad, Cakana, Andrew, Gorin, Norbert Claude, de Witte, Theo, Harousseau, Jean Luc, Morris, Curly, Gahrton, Gösta · 2012 · Journal of Clinical Oncology

Abstract

Purpose: This prospective multicenter phase III study compared the efficacy and safety of a triple combination (bortezomib-thalidomide-dexamethasone [VTD]) versus a dual combination (thalidomide-dexamethasone [TD]) in patients with multiple myeloma (MM) progressing or relapsing after autologous stem-cell transplantation (ASCT). Patients and Methods: Overall, 269 patients were randomly assigned to receive bortezomib (1.3 mg/m 2 intravenous bolus) or no bortezomib for 1 year, in combination with thalidomide (200 mg per day orally) and dexamethasone (40 mg orally once a day on 4 days once every 3 weeks). Bortezomib was administered on days 1, 4, 8, and 11 with a 10-day rest period (day 12 to day 21) for eight cycles (6 months), and then on days 1, 8, 15, and 22 with a 20-day rest period (day 23 to day 42) for four cycles (6 months). Results: Median time to progression (primary end point) was significantly longer with VTD than TD (19.5 v 13.8 months; hazard ratio, 0.59; 95% CI, 0.44 to 0.80; P = .001), the complete response plus near-complete response rate was higher (45% v 21%; P = .001), and the median duration of response was longer (17.9 v 13.4 months; P = .04). The 24-month survival rate was in favor of VTD (71% v 65%; P = .093). Grade 3 peripheral neuropathy was more frequent with VTD (29% v 12%; P = .001) as were the rates of grades 3 and 4 infection and thrombocytopenia. Conclusion: VTD was more effective than TD in the treatment of patients with MM with progressive or relapsing disease post-ASCT but was associated with a higher incidence of grade 3 neurotoxicity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2011.37.4918

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

Metadata

Authors
Garderet, L., Iacobelli, S., Moreau, P., Dib, M., Lafon, I., Niederwieser, D., Masszi, T., Fontan, J., Michallet, M., Gratwohl, A., Milone, G., Doyen, C., Pegourie, B., Hajek, R., Casassus, P., Kolb, B., Chaleteix, C., Hertenstein, B., Onida, F., Ludwig, H., Ketterer, N., Koenecke, C., van Os, M., Mohty, M., Cakana, A., Gorin, N. C., de Witte, T., Harousseau, J. L., Morris, C., & Gahrton, G.
Venue
Journal of Clinical Oncology
Published
2012-07-10
Volume
30
Issue
20
Pages
2475-2482
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2150878522
Cited by
190
References
8
FWCI
16.13
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.